with advanced melanoma and were strongly correlated with the absence of antigen-1 specific T cells (13). In contrast, decreased frequencies of MDSCs were shown when 2 melanoma patients were treated with BRAF inhibitors (14), or anti-CTLA4 blocking 3 antibodies (15). 4 Although the detailed molecular mechanisms remain to be elucidated, a number of 5 inflammatory modulators, including GM-CSF (5, (16) (17) (18) (19) , IL6 (17, 19) and TNF-α (19, 20) 6 have been suggested to contribute to the induction and expansion of MDSCs. Recently, 7
we and others proposed that PGE2 is indispensable for the induction and maintenance of 8
MDSCs in cancer patients. Co-culture with tumor cells secreting PGE2 or treatment with 9 PGE2 was shown to enhance the suppressive functions of monocytes on T cells. 10
Furthermore, inhibition of cyclooxygenase-2 (COX-2), the enzyme catalyzing the 11 synthesis of PGE2, potently rescued suppression of T cells mediated by MDSCs (9, 21) . 12
Despite the recent advances in our understanding of how MDSCs suppress T cell 13 responses, much less is known how NK cell responses are influenced by MDSCs. In 14 tumor-bearing mice, MDSCs were shown to suppress NK cell activation and cytolytic 15 capacity via membrane-bound TGF-β (22, 23). In contrast, it has been proposed that 16
MDSCs may also exert a stimulatory function on NK cells through ligation of the 17 NKG2D receptor (24) . In human cancers, it is less documented how MDSCs interact with 18 NK cells. A recent study showed that suppression of NK cells by moMDSCs was 19 mediated through the ligand of NKp30 in patients with hepatocellular carcinoma (25) . 20
To elucidate the role of tumor-derived PGE2 in the generation of MDSCs, we utilized 21 freshly isolated moMDSCs from patients with advanced melanoma, as well as an in vitro 22
Research. lysates were prepared from pellets and the blots were developed as previously described 1 (27). In brief, equal amount of protein (50 μg) were loaded and detections of each protein 2 were performed using primary monoclonal antibodies (mAb), including anti-p38MAPK, 3
anti-phospho(Thr180/182)-p38MAPK, anti-ERK, anti-phospho(Thr202/Tyr204)-ERK, 4
anti-AKT, anti-phospho(Ser473)-AKT (Cell Signaling). Beta-actin was used as loading 5 control (Sigma-Aldrich). The membrane was then stained with horse-radish-peroxidase-6 conjugated secondary antibodies (Cell Signaling), incubated in LumiLight Western 7
Blotting Substrate™ (Roche Diagnostics), and recorded in a LAS3000 system (Fuji). 8
Flow cytometry and fluorochrome-conjugated antibodies 9
Detailed information of antibodies utilized in this study is summarized in Table S2 . All data were first analyzed in the software mentioned above and summarized by Prism 20
Version 6 software (GraphPad). All data were first tested for normal distribution, 21 thereafter differences among groups were analyzed by student t-test or non-parametric, 22
Research. 
TGF-β is the major suppressive mechanism employed by patient-derived moMDSCs 14
We next investigated the molecular basis of suppression mediated by patient-derived 15 moMDSCs. As shown in Figure 2A demonstrated that PGE2 increased the expression of CD14 on monocytes while the 9 expression of HLA-DR was down-regulated ( Figure 3A and B) . Expression of other 10 myeloid cell markers including; CD16, CD80, DC-Sign, CD33 and CD137 (4-1BB), 11
were not altered between control-cultured and PGE2-treated monocytes ( Figure S2A) . 12
Intracellularly, p38MAPK and ERK pathways were phosphorylated in monocytes, as a 13 result of PGE2 treatment ( Figure 3C ). This was also the case in freshly isolated Mann-Whitney non-parametric U test, *, p<0.05; **, p<0.01. 10 
